In re application of	:	Saxon et al.
App. No.	:	09/847,208
Filed	:	May 1, 2001
For	:	FUSION MOLECULES AND TREATMENT OF IgE-MEDIATED ALLERGIC DISEASES
Examiner	:	Phuong N. Huynh
Art Unit	:	1644

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: United States Patent and Trademark Office, P.O. 2327, Arlington, VA 22202, on

September 26, 2002
(Date)

Ginger R. Dreger, Reg. No. 33,055

UNITED STATES PATENT AND TRADEMARK OFFICE BOX AF
P.O. Box 2327
Arlington, VA 22202

Sir:

Transmitted herewith is:

(X) An Amendment and Response to Final Office Action in the above-identified application.

(X) An article referenced in the above documents entitled, "A Novel Human Immunoglobin Fcγ-Fcε Bifunctional Fusion Protein Inhibits FcεRI-mediated Degranulation", Zhu *et al.*, *Nature Medicine*, Volume 8 (5): 518-521 (2002).

The fee has been calculated as shown below:

CLAIMS AS FILED

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE
Total Claims	19	—	72	= 0 ×	$9	= $0
Independent Claims	2	—	5	= 0 ×	$42	= $0
If application has been amended to contain multiple dependent claim(s), then add					$140	= $0
Time Extension Fee						$0
				TOTAL ADDITIONAL FEE FOR THIS AMENDMENT		$0

(X) The present application qualifies for small entity status under 37 C.F.R. § 1.27.

(X) Return prepaid postcard.

(X) Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Ginger R. Dreger
Registration No. 33,055
Attorney of Record
Customer No. 20,995

W:\DOCS\EJD\EJD-1385.DOC

UC067.002A

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Saxon *et al.*	Group Art Unit 1644
Appl. No.	:	09/847,208	
Filed	:	May 1, 2001	
For	:	FUSION MOLECULES AND TREATMENT OF IgE-MEDIATED ALLERGIC DISEASES	
Examiner	:	Phuong N. Huynh	

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on

September 26, 2002
(Date)

Ginger R. Dreger, Reg. No. 33,055

AMENDMENT AND RESPONSE TO FINAL OFFICE ACTION

Assistant Commissioner for Patents
Washington, D.C. 20231

Please do not enter Paper 10/31/02

Dear Sir:

The present communication is responsive to the Final Office Action mailed on July 2, 2002 (Paper No. 12). Applicants respectfully request reconsideration of the application in view of the following Amendment and Remarks.

AMENDMENT

In accordance with 37 C.F.R. § 1.121, please amend the application as follows.

IN THE CLAIMS:

Please cancel Claims 1-6, 22-27, 29-30, 40-54 and 73-76.

Please insert new claims 77-95, which read as follows:

77. (New) An isolated fusion molecule comprising an IgG heavy chain constant region sequence capable of binding to an IgG inhibitory receptor functionally connected to an IgE heavy chain constant region sequence capable of binding to an IgE receptor.